New detalimogene bladder cancer data send the minnow’s stock up 47%.
ApexOnco Front Page
Recent articles
The response rate jumps to 30% with higher doses of IMA402.
Bezuclastinib plus Sutent could become standard of care in second-line GIST.
After more discontinuations, a new deal brings in fresh blood.
The CD70-targeting CTX131 heads for the scrapheap.
Harmoni-A hits, backing a quiet disclosure about the Harmoni trial.
BG-75202 features among several projects starting first-in-human trials.
Inhibrx reveals three deaths in phase 1, but all predate screening protocols.
